Home > Riviste > Minerva Biotechnology and Biomolecular Research > Fascicoli precedenti > Minerva Biotechnology and Biomolecular Research 2021 June;33(2) > Minerva Biotechnology and Biomolecular Research 2021 June;33(2):53-64

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  BIOTECHNOLOGICAL AND PHARMACOLOGICAL DEVELOPMENTS IN THE MODIFICATION OF CHRONIC INFLAMMATION-INDUCED DISEASES 

Minerva Biotechnology and Biomolecular Research 2021 June;33(2):53-64

DOI: 10.23736/S2724-542X.21.02762-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Application features of biological therapy in patients with autoimmune diseases

Natalia KOZAK 1 , Olena BARABANCHYK 2, Mariia SOBCHENKO 1, Nataliia MOLOCHEK 2, Nadiia DOLGAIA 2, Yuri PENCHUK 2, Galyna MYKHALCHYSHYN 1

1 Bogomolets National Medical University, Kyiv, Ukraine; 2 Educational and Scientific Center, Institute of Biology and Medicine, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine



The article presents modern data on the use of a wide range of immunobiological drugs in various autoimmune rheumatic diseases. The results of numerous clinical studies are presented regarding the effectiveness and safety of the latest promising drugs and describe the features of expediency and sequence of appointment, dosage, and duration of use of registered drugs in specific nosologies and various clinical forms of rheumatic diseases.


KEY WORDS: Therapeutics; Rheumatic diseases; Clinical trial

inizio pagina